[Intraperitoneal and intrapleural two channel chemotherapy by cisplatinum (DDP) and sodium thiosulfate for the treatment of ovarian cancer].
We administrated cis-platinum 70-100 mg/m2 bolus, intraperitoneally or intrapleurally without diluting in saline, simultaneously combined with intravenous injection of sodium thiosulphate 1 gr/hr for 12 hours continuously or additional loading of sodium thiosulphate 4-6 g bolus on the initiation. The procedure does not require transfusion of specific hydration and keeps urine volume at a certain level, much less diuretics. For the treatment of 6 gynecological malignancies (2 primary ovarian carcinoma, 1 recurrent ovarian carcinoma, 1 pseudomyxoma peritonei, 1 clear cell carcinoma of cul de sac and 1 metastatic pleuritis carcinomatosa due to uterine cervical carcinoma) 12 courses treatments have been performed, without inducing nephrotoxicity except mild vomiting. All six cases are evaluable for efficacy according to Saito-Koyama criteria at this time: 4 CRs including 2 CRs for ascites and pleural effusion, 1 NC and 1 PD. This Two-Channel Chemotherapy (TCC) seems to be an important modality of chemotherapy for ovarian carcinoma in future.
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage*; D003536:Cystadenocarcinoma / Q000188:drug therapy; D004359:Drug Therapy, Combination; D004715:Endometriosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010529:Peritoneal Cavity; D010994:Pleura; D013885:Thiosulfates / Q000008:administration & dosage*
D013885:Thiosulfates; C017717:sodium thiosulfate; D002945:Cisplatin